Acute Coronary Syndromes
Risk Factors and Prevention
I very much enjoyed my membership of the Board of the ESC during many years.
It gives me great satisfaction to see the ESC as a leading professional organization
Dr Frans Van de Werf gained his MD in 1972 from the University of Leuven, Belgium. He has made his PhD on diastolic heart function and the genesis of the third heart sound. He was the first to give tPA to patients with an acute myocardial infarction and became involved in the organization of many multicentre trials of antithrombotic therapy in acute coronary syndromes. He has published over 700 peer reviewed papers. Dr Van de Werf is currently Senior Professor of Cardiology at the department of cardiovascular sciences of the University of Leuven.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease